Harvey works in the fields of biotechnology, biochemistry, molecular biology and organic chemistry, with particular expertise in antibodies and immunology, gene therapy, diagnostics and pharmaceutical chemistry.

He specialises in the area of contentious inter partes proceedings before the European Patent Office, and has considerable experience in both oppositions and appeals. He applies this first-hand knowledge to his prosecution practice so as to maximise the strength of his client's patents against subsequent opposition or litigation. He is proficient at handling contentious cases involving parallel proceedings in multiple jurisdictions, and has considerable experience in the conduct of pan-European litigation.  He also has expertise in the procurement of and challenge to SPCs, in regulatory data protection and marketing exclusivity, and in the patent and regulatory law surrounding orphan drugs. He has been involved in numerous key disputes within the biotechnology space, including Ladner / McCafferty (phage display), Noelle / Lederman (antibodies to CD40CR), and the oppositions against the Queen estate (antibody humanisation). He has successfully defended valuable patents protecting significant therapeutic drugs including Avonex® (interferon beta), Temodal® (temozolomide), Clarinex® (desloratadine), Myozyme® (alpha glucosidase), Lexiva® / Telzir® (fosamprenavir), and Soliris® (eculizumab).

Harvey's principal clients include Biogen Idec Inc., Genzyme Corporation, Abbott Laboratories, Dyax Corp., Schering Corporation / Merck & Co., Inc., and The Procter & Gamble Company.